Company intelligence / Profile preview

OrthoSpace

Caesarea, Israel

Ownership: Private
Development stage: Other

Overview

OrthoSpace developed InSpace, a biodegradable subacromial balloon spacer for treatment of massive irreparable rotator cuff tears; the device has a long clinical history with over 20,000 patients treated in more than 30 countries, was CE-marked in Europe, under clinical study in the US at the time of acquisition, and later received FDA clearance in 2021 under Stryker.[2][3][5]

Therapeutic areas: RheumatologyOther
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on OrthoSpace.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrthoSpace.

Explore the full profile